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Gene silencingSchizophrenia is a complex neuropsychiatric disorder that involves disturbances in neural circuitry and syn-
aptic function. The exquisite network architecture and capacity for discreet post-synaptic remodeling of neu-
rons requires coordination by an elaborate intracellular network of molecular signal transduction systems.
The redundancy of these networks means that many combinations of gene variants have the potential to
cause system dysfunction that manifest as related neurobehavioural syndromes. Recent investigation has
revealed that posttranscriptional gene regulation and associated small non-coding microRNA (miRNA), are
likely to be important factors shaping the topography of these networks. miRNA display complex temporos-
patial expression patterns in the mammalian brain and have the potential to regulate thousands of target
genes by functioning as the speciﬁcity factor for intracellular gene-silencing machinery. They are emerging
as key regulators of many neurodevelopmental and neurological processes as their dysregulation could
lead to pervasive changes in the network structure during development and in the mature brain that are
highly signiﬁcant in the pathophysiology of schizophrenia. This review looks at mounting evidence that mature
miRNA levels are altered in both the cerebral cortex and peripheral blood mononuclear cells (PBMCs) in schizo-
phrenia. It also examines compelling evidence that the underlying miRNA biogenesis machinery and miRNA
genes themselves are subject to disease-associated genetic mutation and epigenetic inﬂuence. Signiﬁcantly,
these changes in miRNA expression and associatedmachinery may represent new targets for pharmaceutical de-
velopment, and the identiﬁcation of miRNA signatures in PBMCs suggest that miRNA biomarkers of schizophrenia
may also provide the basis for new clinical diagnostics. These developments have tremendous potential and high-
light the signiﬁcance of this avenue of research.
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Schizophrenia is a debilitating psychotic disorder characterized by
a diverse range of symptoms and cognitive impairments. While the
neuropathology is relatively subtle and inconsistent at the anatomi-
cal, cellular and molecular levels, developments in neural imaging
and histological techniques are reﬁning our understanding of the
spectrum of changes in gross anatomy, neural circuitry and cytoarch-
itecture. In recent years, the molecular neuropathology has also been
revolutionized by the development of high-throughput genomics and
proteomics. These allow a systems-level approach to understanding
the role of molecular networks and interaction rather than individual
candidate genes. A redundant pathways-based approach to the neu-
robiology of schizophrenia is also consistent with the genetics of the
disorder, which is complex and polygenic. Many common gene vari-
ants, each with a weak effect size in combinatorial patterns of inheri-
tance probably convey risk for the disorder through redundant
pathways rather than as highly speciﬁc deﬁcits. In this systems-view
of schizophrenia, nodes of gene regulation will be particularly signiﬁ-
cant as they shape the topology of molecular pathways and networks
and have the most inﬂuence on their behavior. These nodes can take
many forms and interact at all levels of gene expression from DNA
through to protein. While transcription factors and protein based signal
transduction pathways are usually considered in this context, small
non-coding RNA molecules known as microRNA (miRNA) have
emerged as signiﬁcant regulatory factors. These are expressed in a de-
velopmental and tissue-speciﬁc manner and are thought to regulate
the majority of human genes (Lewis et al., 2005; Xie et al., 2005).
Their inﬂuence, however, may be harder to trace than transcription fac-
tors and signal transduction molecules because their diverse interac-
tions and capacity affect both RNA stability and translation. These
small RNAs (18 to 26 nucleotides) are the speciﬁcity factors for a large
multi-protein effector complex known as the RNA-induced silencing
complex (RISC). The RISC, which is also responsible for the RNA inter-
ference pathway, interacts with its target genes through the
sequence-speciﬁc base pairing, particularly at nucleotides 2 to 8 (seed
region) and usually with the 3′UTR of speciﬁcally targeted mRNA
(Gebauer et al., 2004; Lewis et al., 2005; Pillai et al., 2005) (Fig. 1). Al-
though the ﬁrst published account of a miRNA appeared nearly
20 years ago (Lee et al., 1993), it is only inmore recent years that the di-
versity of these small regulatory RNA has been acknowledged. The
widespread expression and activity of miRNA in the brain (Cao et al.,
2006) support their implication in numerous neurological disorders.
Considering that each miRNA is potentially manipulating the ex-
pression of hundreds of target genes, the clinical implications of an
abnormality or disturbance of this system are substantial, particularly
if such abnormality occurs during development of the central nervous
system. Studies have shown that the global depletion of Dicer in the
brain is associated with dopaminergic behaviors and Parkinson's-
like symptoms. Deletion of Dicer in dopamine neurons results in the
progressive loss of these neurons and an increase in Parkinson's-like
behaviors (such as reduced locomotion and increased immobility, be-
havioral changes and other neuronal defects) (Cuellar et al., 2008;
Kim et al., 2007). miRNA expression has been shown to be altered
in the midbrain of Parkinson's patients, suggesting that miRNA dysre-
gulation could contribute to some aspects of this disease (Kim et al.,
2007). In fragile X mental retardation, the gene responsible for the
disorder FMR1, encodes the protein FMRP, which is present in synap-
ses and is part of the RNA-induced silencing complex (RISC). Loss of
FMRP impairs the function of RISC-mediated gene silencing, resulting
in altered synaptic development (Jin et al., 2004). In Tourette's syn-
drome, a mutation in a miRNA binding site in the 3′UTR of SLITRK1
(a protein involved in neurite outgrowth) has been associated with
the disorder (Abelson et al., 2005). Additionally, multiple studies
have also suggested a link between miRNA dysregulation and Alzhei-
mer's disease, although the speciﬁc molecular mechanisms remainunknown (Hebert et al., 2009; Nelson et al., 2010; Wang et al.,
2010). In schizophrenia, miR-137 was recently shown to be highly as-
sociated (p=1.6×10−11) with the disorder in one of the largest ge-
nome wide association studies conducted to date (Schizophrenia
Psychiatric Genome-Wide Association Study GWAS Consortium,
2011).
miRNA can elicit a broad effect on gene expression and functional
pathways and thus have important implications for neuropsychiatric
disorders, such as schizophrenia, which have been characterized by a
dysregulation of multiple pathways. These complex systems repre-
sent a signiﬁcant challenge to both the investigation of the underlying
biological causes and efforts to develop effective therapies. Examining
the role of miRNA in coordinating signaling in psychiatric disease may
explain both dysregulation of multiple pathways and offer a window to
novel therapies that can target entire gene networks. Here we review
the research data gathered from genetic, living donor, postmortem
brain and animal studies, and discuss functional analysis and biological
implications ofmiRNA dysregulation and pathophysiology.We also dis-
cuss the potential clinical utility of miRNA as novel biological markers
and therapeutic targets for schizophrenia.
Evidence of miRNA dysregulation in schizophrenia
Postmortem analysis of cortical miRNA expression
Expression proﬁling studies in postmortem gray matter of individ-
uals with schizophrenia have implicated numerous miRNA in the dis-
order. Utilizing a case–control approach, data has been compiled from
various brain regions including the prefrontal cortex (BA9, BA10,
BA46), parietal (BA7) and temporal cortices (BA22) using a variety
of microarray platforms and quantitative RT-PCR (qPCR) techniques.
The ﬁrst of these studies examined miRNA expression using a cus-
tom microarray (miRBase version 7.0) in total RNA extracted from
postmortem dorsolateral prefrontal cortex (DLPFC) (BA9) (Perkins
et al., 2007). This analysis of 13 schizophrenia samples and 21 con-
trols identiﬁed 15 differentially expressed miRNA including 14
miRNA with decreased expression and one with increased expression
in the schizophrenia group (Table 1). This was then validated by qPCR
in a random selection of 4 cases and 4 controls. The qPCR was broadly
consistent with the array with the exception of miR-7, indicating in-
creased expression in the schizophrenia group. Using a very similar ap-
proach (Thomson et al., 2004), we conducted miRNA proﬁling analysis
(miRBase v7.0) of the superior temporal gyrus (BA22) and reported a sig-
niﬁcant increase in expression of miR-181b and let-7b. We also con-
ﬁrmed differential expression of miR-181b by Northern blot and qPCR
(Beveridge et al., 2008). Using an improved custom array (miRBase
v7.1) printed with an LNA modiﬁed probe set including U6 small RNA
controls, we reanalyzed an enlarged cohort (n=21 pairs of cases and
controls) and identiﬁed a further 59 mature miRNA upregulated in
the schizophrenia group including miR-181b (Beveridge et al., 2008,
2010). As miRNA are extensively regulated through their biogenesis
pathway in addition to underlying transcription (Thomson et al.,
2006) we moved away from a global normalization strategy and used
U6 snoRNA as reference. While there are risks of artifact in this ap-
proach, it provides a capacity to detect global changes inmiRNA expres-
sion that aremissedwhenmiRNA expression is used as a normalization
factor. These results were highly consistent with qPCR analysis of the
entire cohort, and the schizophrenia-associated change in global
miRNA expression was supported by analysis of uncapped RNA, which
showed a signiﬁcant increase in small RNAs (Beveridge et al., 2010).
Similarly, we also reported signiﬁcant upregulation of miRNA expres-
sion in DLPFC (BA9) with 26 miRNA displaying increased expression
in the schizophrenia group (Beveridge et al., 2010). A large proportion
of these samples (14 cases and 9 controls) were derived from the
same individuals andmiRNA expressionwas highly correlated between
the two regions (unpublished). We also observed 11 miRNA displaying
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Fig. 1. Overview of miRNA processing. miRNA are encoded by their own genes or from the introns of protein-coding genes and are usually transcribed by RNA polymerase II. Inside
the nucleus, the microprocessor complex (comprised of the ribonuclease Drosha and nuclear protein DGCR8) processes the primary miRNA transcripts into 70-nucleotide pre-
miRNA. Exportin-5 then transports pre-miRNA into the cytoplasm where it is then processed into an RNA duplex by the ribonuclease Dicer. Although either strand of the duplex
may potentially act as a functional miRNA, only one strand of the RNA duplex assembles into the RNA-induced silencing complex (RISC) with Argonaute 2 and consequently acts on
its target gene to reduce mRNA and/or protein levels. ORF: open reading frame.
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most striking feature conserved between both regions was the upregu-
lation of miR-107 and the entire miR-15 family, which are predicted to
share most of their target genes and would be expected to exert func-
tionally convergent inﬂuence on cortical gene expression (Beveridge
et al., 2010).
Mellios et al. (2009) utilized a frontal cortex (BA10) cohort to in-
vestigate the association between miRNA (miR-30a and miR-195)
and schizophrenia candidate gene BDNF protein as well as neuropep-
tide Y, somatostatin, and parvalbumin mRNAs. It was reported that
miR-195 expression, a member of the miR-15 family, shown to be
upregulated in schizophrenia (Beveridge et al., 2010), was inversely
associated with BDNF protein. This study also suggested that miR-195
might operate as a ﬁne-tuner of the BDNF protein, which consequently
could contribute to the prefrontal deﬁcits in someGABAergicmRNAs. In
another study by Mellios et al. (2010), the expression of the estrogen-
sensitivemiR-30bwas determined in the prefrontal (BA10) and parietal
(BA7) cortices. It was reported that female schizophrenia subjects dis-
played reduced levels of mature miR-30b transcripts while primary
and precursor transcripts were unchanged.
The glutamate receptor ionotropic delta 1 (GRID1), gene previously
implicated in schizophrenia (Fallin et al., 2005; Guo et al., 2007), also en-
codes the intronic precursor for miR-346. In view of this, Zhu et al.
(2009) sought to investigate both the correspondingmaturemRNA tran-
script and miRNA in a cohort of schizophrenia and bipolar subjects. The
expression of miR-346 and GRID1 was shown to be reduced in schizo-
phrenia subjects, though GRID1 was slightly above the threshold for sig-
niﬁcance (p=0.08). Interestingly, miR-346 and GRID1 expressionswere
highly correlated in the control and bipolar samples (r2>0.47), but
much less correlated in the schizophrenia samples (r2=0.17). It was
suggested that since miR-346 and GRID1 mRNA are derived from the
same primary transcript, the difference in correlation most likely arises
from altered post-transcriptional processing or decreased stability of
the transcripts in schizophrenia.
Utilizing a high-throughput qPCR approach (TaqMan low density
array), Kim et al. (2010) proﬁled miRNA expression (miRBase v13.0)in a cohort of schizophrenia and bipolar subjects (Stanley collection,
DLPFC BA46). This analysis reported that 7 miRNA displayed increased
expression in the schizophrenia group (miR-7, miR-34a, miR-132,
miR-132*, miR-154*, miR-212 and miR-544). A total of 15 miRNA
were altered in the bipolar group, though presented an even split of
8 downregulated and 7 upregulated miRNA. Differentially expressed
miRNA were also subjected to single tube qPCR validation (normalized
with respect to U48 snoRNA) with 9 out of 21 consistent with the array.
Discordance between array and single tube qPCR was possibly due to
differences in normalization strategy (median polishing approach in
the array and conventional housekeeping genes in free PCR) or the
effect of cDNA pre-ampliﬁcation in array analysis. The trend toward
upregulation in the schizophrenia group is consistent with our study
of the same brain region by Santarelli et al. (2011) as well as that of
the DLPFC (BA9) and temporal cortex by Beveridge et al. (2008, 2009).
In a large postmortem cohort consisting of 37 schizophrenia and
37 control samples (NSW, TRC) from the DLPFC (BA46), we reported
that 25 miRNA displayed increased expression and 3 showed reduced
expression in schizophrenia after correction for multiple testing
(SAM) (Santarelli et al., 2011). In this study we utilized a commercial
bead array platform (Illumina) and normalized miRNA expression
against the expression of small nucleolar RNA (miRBase version
9.1). qPCR was also used to validate a subset of 6 out of 10 differen-
tially expressed miRNA.
Moreau et al. (2011) also used a high-throughput qPCR approach
(TaqMan human miRNA assay, miRBase v9.2) to examine miRNA ex-
pression in postmortem schizophrenia and bipolar disorder in DLPFC
(BA9) tissue from the Stanley array collection (n=35/group). Nor-
malization was performed with respect to the geometric mean of
three stably expressed snoRNAs. Using Bayesian network averaging,
a total of 19 miRNA appeared to display altered expression in the
schizophrenia group, 10 downregulated (miR-22, miR-33, miR-
106b, miR-138, miR-151, miR-210, miR-324-3p, miR-338, miR-339
and miR-425) and 9 upregulated (miR-27b, miR-148b, miR-193b,
miR-148b, miR-186, miR-190, miR-301, miR-99a and miR-545). No-
tably, the miRNA with increased in expression in the schizophrenia
Table 1
Schizophrenia-associated miRNA.
Study Type Brain region Species Schizophrenia-associated miRNA
Hansen et al. (2007) miR-SNP N/A Human miR-198, miR-206
Perkins et al. (2007) Postmortem brain DLPFC (BA9) Human [Upregulated] miR-106b, miR-7
[Downregulated] miR-26b, miR-30b, miR-29b, miR-195, miR-92, miR-30a, miR-30d,
miR-20b, miR-29c, miR-29a, miR-212, miR-24, miR-30e, miR-9*
Beveridge et al. (2008) Postmortem brain STG (BA22) Human miR-181b
Stark et al. (2008) 22q11.2
hemizygous
deletion
PFC and
Hippocampus
Mouse [Downregulated] miR-106b, miR-134, miR-140*, miR-151, miR-18, miR-185,
miR-194, miR-194, miR-212, miR-224, miR-323, miR-325, miR-362, miR-383,
miR-409, miR-422b, miR-491, miR-494, miR-532, miR-540, miR-669a, miR-673,
miR-674, miR-674*, miR-708, miR-93,
Xu et al. (2008) CNV N/A Human [CNV gain] 14q32.13-32.2, 1p34.2, 6p22.3, 16p13.2, 12q24.23, 3p24.1, 3p26.1,
4q34.1, 16p13.2
[CNV loss] 22q11.21, 3q22.2, 9q23, 19q13.12, 5q31.1, 10q21.1
Beveridge et al. (2010) Postmortem brain STG (BA22) Human [Upregulated] let-7e, miR-107, miR-125b, miR-128a, miR-128b, miR-129, miR-130a,
miR-133b, miR-138, miR-146b, miR-148a, miR-150, miR-152, miR-155, miR-15a,
miR-15b, miR-16, miR-17-3p, miR-17-5p, miR-181b, miR-195, miR-197, miR-199a*,
miR-19a, miR-20a, miR-222, miR-23a, miR-24, miR-26b, miR-26b, miR-27b, miR-28,
miR-296, miR-328, miR-330, miR-335, miR-338, miR-339, miR-340, miR-373*, miR-381,
miR-409-5p, miR-432*, miR-452*, miR-455, miR-484, miR-485-5p, miR-486, miR-487a,
miR-489, miR-494, miR-499, miR-502, miR-517a, miR-517c, miR-518b, miR-519d,
miR-520a*, miR-520 g, miR-9*, miR-99a
Beveridge et al. (2010) Postmortem brain DLPFC (BA9) Human [Upregulated] let-7d, miR-101, miR-105, miR-107, miR-126*, miR-128a, miR-153,
miR-15a, miR-15b, miR-16, miR-16, miR-181a, miR-181b, miR-181b, miR-181d,
miR-184, miR-195, miR-199a, miR-20a, miR-219, miR-223, miR-26b, miR-27a,
miR-29c, miR-302a*, miR-302b*, miR-31, miR-33, miR-338, miR-409-3p, miR-512-3p,
miR-519b, miR-7
Feng et al. (2009) miR-SNP N/A Human let-7f-2, miR-188-3p, pre-miR-18b, miR-325-3p, pre-miR-502, pre-miR-505, miR-509-3p,
miR-510-3p, miR-660
Kocerha et al. (2009) Pharmacological PFC Mouse miR-219
Mellios et al. (2009) Postmortem brain Frontal cortex
(BA10)
Human [Downregulated] miR-30e, miR-195
Sun et al. (2009) miR-SNP N/A Human miR-502, miR-510
Tabares-Seisdedos et al.
(2009)
CNV N/A Human miR-124-1, miR-320, miR-383, miR-486, miR-596, miR-597, miR-598,
Zhu et al. (2009) Postmortem brain DLPFC (BA46) Human miR-346
Kim et al. (2010) Postmortem brain DLPFC (BA46) Human [Upregulated] miR-132, miR-132*, miR-154*, miR-212, miR-34a, miR-544, miR-7
Mellios et al. (2010) Postmortem brain Frontal cortex
(BA10)
Human [Downregulated] miR-30b
Xu et al. (2010) miR-SNP N/A Human miR-24, pre-miR-30e, miR-30e
Gardiner et al. (2011) Peripheral tissue
(PBMC)
N/A Human [Downregulated] miR-107, miR-1275, miR-128, miR-130b*, miR-134, miR-148b, miR-150*,
miR-151-3p, miR-16-2*, miR-181a, miR-200c, miR-224, miR-28-3p, miR-28-5p, miR-29b-1*,
miR-30e*, miR-31, miR-329, miR-335*, miR-342-5p, miR-409-3p, miR-431, miR-432,
miR-486-3p, miR-487b, miR-544, miR-574-3p, miR-576-5p, miR-584, miR-625*, miR-664,
miR-877, miR-99b,
Lai et al. (2011) Peripheral tissue
(PBMC)
N/A Human [Upregulated] miR-34a, miR-449a, miR-548d, miR-564, miR-572, miR-652,
[Downregulated] miR-432
Moreau et al. (2011) Postmortem brain DLPFC (BA9) Human [Upregulated] miR-148b, miR-151 miR-27b, miR-301, miR-545, miR-639 [downregulated]
miR-106b, miR-138, miR-193b, miR-210, miR-22, miR-324-3p, miR-338, miR-339, miR-425
Santarelli et al. (2011) Postmortem brain DLPFC (BA46) Human [Upregulated] miR-105, miR-134, miR-148b, miR-150, miR-152, miR-154, miR-17-5p, miR-187,
miR-193a, miR-199a*, miR-199b, miR-222, miR-25, miR-328, miR-382, miR-409-3p, miR-423,
miR-425-5p, miR-433, miR-452*, miR-487a, miR-495, miR-502, miR-512-3p, miR-519c,
miR-532, miR-542-3p, miR-548b, miR-590, miR-592, miR-652, miR-767-5p, miR-92b,
The Schizophrenia Psychiatric
Genome-Wide Association
Study GWAS Consortium
(2011)
GWAS N/A Human miR-137
These miRNA were found to have altered expression in multiple studies and displayed consistent changes with regards to the direction of change. Abbreviations: miR-SNP; single
nucleotide polymorphism within a microRNA, DLPFC; dorsolateral prefrontal cortex, BA; Brodmann's Area, STG; superior temporal gyrus, CNV; copy-number variant, PBMC; periph-
eral blood mononuclear cells, GWAS; genome-wide association study.
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to a 10% reduction compared to a 10–20% increase). The liquid bead
array-based FlexmiR v2 assay was used for cross-platform validation.
Using 7 samples, 8/10 miRNA were shown to have expression patterns
that correlatedwell between platforms (r=0.76–0.98).While the bipo-
lar groups differentially expressedmiRNAwere consistently downregu-
lated, with 24 having signiﬁcantly reduced expression, there was not
enough similarity between the two psychotic illnesses, in our opinion,
to suggest that there is a common miRNA deﬁcit associated with
psychosis.
Collectively this research has identiﬁed numerousmiRNA associated
with schizophrenia. However, while some have displayed consistent
changes across independent studies, there are many others that havenot. A total of 16 miRNA are associated with increased expression in
multiple studies (miR-105, miR-128a, miR-15a, miR-15b, miR-16,
miR-17, miR-199a*, miR-20a, miR-222, miR-34a, miR-452*, miR-486,
miR-487a,miR-502,miR-652,miR-7) and 11miRNAwithdecreased ex-
pression (miR-106b, miR-151, miR-20b, miR-224, miR-30a, miR-30b,
miR-30d, miR-30e, miR-383, miR-432, miR-505) (Table 1 and Supple-
mentary Table 1). These miRNA have been reported to alter expression
in the same direction in two or more studies, or are associated with a
miR-SNP or CNV. There are also a number of miRNA, which are con-
sistently reported to display signiﬁcantly altered expression, except
in opposing directions (Supplementary Table 2). Some miRNA
show consistent changes in postmortem studies, while being altered in
the opposite direction in peripheral tissues. Some of these discrepancies
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methods (total RNA vs. small RNA enriched, electrophoresis vs. solvent
extraction), ampliﬁcation, array platform, chemistry and normalization
methods. While biological variation arising from regional differences in
cytoarchitecture and cellular composition are difﬁcult to control, the in-
ﬂuence of deﬁned postmortem variables such as age, gender, postmor-
tem interval and brain pH can be adjusted statistically.
The neuropathology of miRNA is an evolving science employing a
wide variety of approaches for tissue collection/extraction, determina-
tion ofmiRNAexpression, normalization and statistical analysis. In future
studies it would be valuable to combine the analysis from multiple cen-
ters using a consistent approach and utilize sequence information, par-
ticularly for miRNA genes to stratify on the basis of genotype, for
example, miR-137. Where possible, it will also be informative to investi-
gate different brain regions, including subcortical nuclei derived from the
same individual. This will establish the difference between brain regions
and genetic background and the extent of miRNA associated neuropa-
thology. It will also be important to reﬁne the extraction of tissue
through laser capture microdissection to determine the inﬂuence of,
and ultimately control for white matter composition, cytoarchitecture
and variance in neural cell populations, as these parameters all vary
within the brain, between individuals and disease status. In view of
these limitations in understanding the neuropathology schizophrenia,
it will also be of great interest to identify disease-associated changes in
miRNA expression beyond the brain. Peripheral tissue samples, such as
blood are more homogenous and can be collected in large numbers
from living patients. Early investigation of peripheral miRNA in schizo-
phrenia and the potential for clinical application is discussed below.
Schizophrenia-associated peripheral miRNA expression
In view of the changes in cortical miRNA expression, their underlying
regulation and genetic association with schizophrenia, particularly miR-
137, it is plausible to suggest that disease associated changes in miRNA
expression may also be detectible in peripheral tissues such as lympho-
cytes. If they are, then these expression signatures may say something
about the underlying mechanism that is consistent with, or not other-
wise observed in brain tissue. For example, they may have some rele-
vance to other aspects of schizophrenia risk, such as the immune
response to maternal infection or cytokine exposure during pregnancy.
miRNA signatures are indicative of a functionally relevant biological
state and therefore may have utility as biomarkers of the disease or dis-
ease associated sub-phenotypes. Diagnosis of schizophrenia is currently
based exclusively on signs and symptoms and requires qualiﬁed psychi-
atric assessment. Diagnosis based on a molecular signature could serve
to reﬁne the diagnosis and in some cases accelerate diagnosis and facili-
tate earlier interventions particularly in remote areas where access to
psychiatric services are limited. miRNA based biomarkers have already
been shown to be useful in the clinical stratiﬁcation of cancer and have
even greater prognostic signiﬁcance than mRNA, possibly because they
are discrete functional entities. Peripheral miRNA expression has also
been investigated in other neurological disorders. In Alzheimer's disease,
miRNA analysis has revealed patterns of altered expression in peripheral
bloodmononuclear cells (PBMCs) (Schipper et al., 2007) aswell as in the
cerebrospinal ﬂuid and brain (Cogswell et al., 2008). Disease-associated
miRNA proﬁles have also been identiﬁed in relation to multiple sclerosis
and its remission status (Cox et al., 2010). PBMCs in particular are an
attractive alternative tissue for proﬁling disease in living patients at
statistically robust numbers. This readily accessible tissue can reﬂect
global disease-associated changes in an underlying genetic disorder
and may have special signiﬁcance where immunological risk factors
are believed to be involved.
We recently investigated the expression proﬁle of PBMCs from 112
patients with schizophrenia and 76 non-psychiatric controls. This
revealed 83 signiﬁcantly downregulated miRNA in the schizophrenia
group, including a large subgroup of miRNA (20%) transcribed from asingle imprinted locus at the maternally expressed DLK1-DIO3 region
on chromosome 14q32 (Gardiner et al., 2011). Similarly, Lai et al.
(2011) identiﬁed a seven-miRNA signature (hsa-miR-34a, miR-449a,
miR-564, miR-548d, miR-572 and miR-652 upregulated; miR-432
downregulated) in an initial cohort of 30 patients with schizophrenia
and 30 controls. This was then validated in an extended cohort of 60
schizophrenia patients, and 30 controls. Signiﬁcantly, miR-432 displayed
schizophrenia-associated decreased expression in both independent co-
horts. The expression of some of these 7 miRNA also correlated with
schizophrenia patients negative symptoms, neurocognitive dysfunction
and mismatch negativity performance. Interestingly, miR-449a signiﬁ-
cantly correlated with most features from the Wisconsin Card Sorting
Test suggesting it might be involved in the executive functioning of the
brain. Both of these studies have identiﬁed peripheral patterns of
miRNA that could have utility as biomarkers for schizophrenia and asso-
ciated sub-phenotypes. However, as most of the subjects reported the
use ofmedication and some exposure to drugs and alcohol, larger studies
with more comprehensive investigation of these confounds are needed
to deﬁne their inﬂuence on miRNA expression in this tissue.
Mechanisms for miRNA dysregulation in schizophrenia
Mutation, genetic association and the alteration of miRNA transcription
and processing
miRNA genes are for the most part expressed from polymerase II
promoters and are regulated by transcription factors and chromatin
structure in a manner synonymous to that of mRNA. These transcripts
are usually in the form of non-coding mRNAs or derived from the in-
trons of protein-coding mRNA. As such, the extent of transcription
will vary with respect to the prevailing regulatory environment and
epigenetic status as it does with any gene. miRNA transcription will
also be dependent on the integrity of conserved sequence motifs in
their promoters and enhancer elements. After transcription, their pro-
cessing into precursor, andmaturemiRNAwill also be dependent on the
integrity of sequences in the primary hairpin that guide the miRNA bio-
genesismachinery. All of these components ofmiRNA genes aremutable
and can give rise to heritable changes in the genomewith functional sig-
niﬁcance to diseases such as schizophrenia.
The ﬁrst studies to speciﬁcally investigate the association of miRNA
polymorphisms and schizophrenia examined 28 brain expressed
miRNA in a Scandinavian cohort (Danish, Swedish Norwegian cases
n=420/163/257, controls n=1006, 177, 293). Interestingly, two miR-
SNPs were identiﬁed to be associated with schizophrenia, residing in
miR-206 (Danish sample p=0.0021) and miR-198 (Norwegian sample
p=0.038), however the functional signiﬁcance of these polymorphisms
was not determined (Hansen et al., 2007). In a similar manner, Sun et al.
(2009) also identiﬁed two schizophrenia-associated miR-SNPs (in miR-
510 and miR-502) in a male Caucasian cohort (n=193 cases and 191
controls). These polymorphisms were also functionally signiﬁcant and
were associated with reduced miRNA processing and thus produced
less precursor and mature miR-502/510 transcripts in vitro. In the case
of miR-502 at least, the reduced processing is thought to be due to the
SNP impairing Drosha cleavage. Feng et al. (2009) also tested the hy-
pothesis is that ultra-rare variants in X-linked miRNAs may predispose
to schizophrenia, consistent with reduced fertility and consequent elim-
ination of high-risk X-linked mutations within a few generations (Rees
et al., 2011). They identiﬁed 8 ultra-rare variants in 3 males with schizo-
phrenia within miRNA precursors (pre-miR-18b, pre-miR-505 and pre-
miR-502) and 5 within the mature transcripts (let-7f-2, miR-188-3p,
miR-325-3p, miR-509-3p, miR-510-3p and miR-660). In a Chinese
case–control study, a new variant was identiﬁed within pre-mir-30e.
This combined with SNPs in the mature miR-30e and miR-24/MAPK14
displayed a weak gene–gene interaction for schizophrenia risk (Xu
et al., 2010). Recently, Begemann et al. (2010) showed that miR-498
binds with increased afﬁnity when the T allele is present in the 3′UTR
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pression of the gene in a genotype-dependent manner.
Perhaps the most exciting miRNA gene to show genetic associa-
tion with schizophrenia is MIR137. The loci containing this gene at
1p21.3 (rs1625579) emerged with the strongest association to
schizophrenia in the most recent GWAS (Schizophrenia Psychiatric
Genome-Wide Association Study GWAS Consortium, 2011). The
gene for this long non-coding RNA transcript (AK094607) is over
100 kb from any protein-coding gene but encodes the primary tran-
script for miR-137. The functional signiﬁcance of this polymorphism
with respect to miR-137 expression is not immediately obvious as it
occurs within the intron of the parent transcript and it may be a
marker SNP for other more functionally signiﬁcant polymorphisms
more proximal to themiRNAhairpin. Furtherworkwill be needed to es-
tablish the function of this mutation or associated polymorphisms with
respect tomiR-137.While this is the ﬁrst report to implicatemiR-137 in
schizophrenia, thismiRNA is expressed in the brain andhas been shown
to regulate adult neurogenesis and neuronal maturation (Smrt et al.,
2010; Szulwach et al., 2010), mechanisms through which variation
could contribute to altered brain function in schizophrenia. Interesting-
ly a number of protein coding genes associated with schizophrenia in
this and other studies are also predicted target genes of miR-137 (in-
cluding transcription factor 4 (TCF4), calcium channel, voltage-
dependent, L type, alpha 1C subunit (CACNA1C), CUB and Sushi multi-
ple domains 1 (CSMD1) and C10orf26) and thus plausibly this gene
could convey riskmediated by a number of genes through a disturbance
of in miRNA function.
Alterations in miRNA Biogenesis
While miRNA are regulated at the level of transcription and are
susceptible to cis-acting mutations like other genes (Han et al.,
2006; Zeng et al., 2005a, 2005b), they are also themselves extensively
post-transcriptionally regulated and are sensitive to changes in the
miRNA biogenesis pathway (Blow et al., 2006; Kawahara et al.,
2007; Thomson et al., 2006; Yang et al., 2006). In respect to this inﬂu-
ence, there is mounting evidence that dysregulation of cellular
miRNA processing and maturation can contribute to the pathophysi-
ology of disease including neurological and neuropsychiatric diseases
such as schizophrenia. In this context it is interesting that copy num-
ber variation and polymorphisms affecting genes in the miRNA bio-
genesis pathway are possibly overrepresented in schizophrenia and
related neurobehavioural syndromes. The best characterized of
these associations is the 22q11.2 microdeletion syndromes known
as DiGeorge or Velo-Cardio-Facial Syndrome (VCFS). These syn-
dromes have a broad range of symptoms including neurobehavioral
problems and cognitive deﬁcits. Approximately 30% of children with
the deletion will develop schizophrenia as they enter adolescence or
early adulthood, one of the highest risk factors for developing the dis-
order, after identical twins or having two parents with schizophrenia
(Bassett et al., 2003; Murphy et al., 1999). It has also been shown that
22q11.2 microdeletions are responsible for introducing new cases of
schizophrenia into the population, accounting for approximately 2%
of sporadic schizophrenia cases (Karayiorgou et al., 1995; Xu et al.,
2008). The most common deletion spans 3 Mb, but a nested 1.5 Mb
deletion contains a number of schizophrenia-associated genes. This
region is conserved within the syntenic region of mouse chromosome
16 and contains nearly all orthologues of the human genes. Stark et al.
(2008) generated a mouse model carrying the equivalent human
1.5 Mb microdeletion. This resulted in a hemizygous deletion of the
Dgcr8 gene (a component of the microprocessor complex in the
miRNA biogenesis pathway) along with the downregulation of 25
brain-related miRNA. They report that abnormal miRNA biogenesis
emerges because of haploinsufﬁciency of the Dgcr8 gene and contributes
to the behavioral and neuronal deﬁcits associated with the 22q11.2
microdeletion. More recently, two other groups have investigatedDgcr8+/− knockout mouse models to examine the effect of Dgcr8 deﬁ-
ciency on miRNA expression neuronal morphology. Schoﬁeld et al.
(2011) reported reduced levels of Dgcr8 and miRNA in the mouse pre-
frontal cortex which emerged throughout development. Consequently
there were altered electrical properties of layer V pyramidal neurons, re-
duced excitatory synaptic transmission and decreased complexity of the
basal neurites. In accordance with this study, Fenelon et al. (2011) also
showed that the Dgcr8+/− knockouts had altered electrical properties
and smaller dendritic spines in later V pyramidal neurons. In addition,
they also observed less layers II and IV neurons overall.
Other components of the miRNA biogenesis family including Dicer
have also been found to be subjected to spontaneous copy number var-
iation. In a genome-wide scan for de novo CNVs in sporadic schizophre-
nia, Xu et al. (2008) identiﬁed a duplication which encompassed the
DICER1 gene and Tabares-Seisdedos et al. (2009) commented that chro-
mosome 8p (which contains 7 miRNA) is a CNV hot-spot for schizo-
phrenia and other disorders such as autism. Increased Dicer gene
dosage is consistent with schizophrenia-associated changes in Dicer
gene expression observed in the DLPFC and elevatedmaturemiRNA ex-
pression (Beveridge et al., 2010; Santarelli et al., 2011).
Postmortem brain studies have also suggested altered miRNA bio-
genesis as a mechanism for miRNA dysregulation in their cohorts.
Perkins et al. (2007) showed that several miRNA with reduced ex-
pression also displayed a reduction in the ratio of mature to primary
transcript, suggesting that miRNA processing may be impaired. Also,
in our studies of BA22/STG and BA9, precursor transcripts (but not
primary) of some upregulated miRNA were also shown to have in-
creased expression. This also highlighted altered miRNA biogenesis as
a mechanism behind the increase in miRNA expression. This was sup-
ported by an increase in the DGCR8 mRNA in both regions (BA22/STG,
BA9) including an increase in DICER mRNA in the DLPFC. Dicer mRNA
was also signiﬁcantly increased in the BA46 cohort, however when uti-
lizing a paired statistical approach there was also a statistically signiﬁ-
cant increase in DGCR8 and Drosha mRNAs as well.
Pharmacological impact
A number of studies have evaluated the impact of various neuro-
leptic drugs on the expression of miRNA. This has particular relevance
when interpreting the results of postmortem studies as most schizo-
phrenia subjects have an extensive antipsychotic treatment history
and the effects on miRNA expression are largely unknown. Perkins
et al. (2007) examined miRNA expression in rats treated with halo-
peridol versus untreated controls and reported that 3 miRNA (miR-
128a, miR-128b and miR-199a) were upregulated in the frontal cortex
as a consequence of this treatment. Notably, each of these miRNA
have been shown to have increased expression in the DLPFC (BA9)
(miR-128a,miR-199a) and STG (miR-128a,miR-128b) of schizophrenia
subjects with a haloperidol treatment history (Beveridge et al., 2010).
In a related study, Zhou et al. (2009) examined the effects of com-
mon bipolar treatments, lithium and sodium valproate on miRNA ex-
pression in the rat hippocampus. They reported a downregulation of
let-7b, let-7c, miR-128a, miR-24a, miR-30c, miR-34a and miR-221
and an upregulation of miR-144, all behaving similarly in both treat-
ments. Further analysis substantiated a link between miR-34a and its
potential target, metabotropic glutamate receptor 7 (GRM7). This has
a particular relevance to schizophrenia with GRM7 as a potential can-
didate gene and miR-34a displaying increased expression in the
DLPFC (BA46)(Kim et al., 2010) and PBMCs (Lai et al., 2011) of schizo-
phrenia subjects.
In a study examining the effects of the selective NMDA receptor an-
tagonist dizocilpine/MK-801 inmice,miR-219was shown to be reduced
in theprefrontal cortex upon drug treatment (Kocerha et al., 2009). Sug-
gestive of a role for miR-219 in NMDA signaling, in vivo inhibition of
miR-219 in the mouse brain caused the upregulation of its target,
calcium/calmodulin-dependent protein kinase II gamma subunit
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paired NMDA receptor signaling and relevant behavioral responses
were observed. They also report that the dizocilpine/MK-801-induced
effects on miR-219 could be diminished by pretreating the mice with
haloperidol and clozapine. miR-219 has been shown to have increased
expression in the DLPFC (BA9) of schizophrenia subjects (Beveridge
et al., 2010) and is consistent with the NMDA receptor hypoactivity hy-
pothesis in schizophrenia.
Functional implications
Target prediction methods and pathway analyses
Several algorithms have been developed to predict miRNA binding
sites within the 3′UTR of target genes, typically taking into account
sequence complementarity, conservation and the thermodynamics
of the miRNA:mRNA duplex. Some methods require strict comple-
mentarity within the seed region while others also assess the conser-
vation of the predicted binding site as an added level of stringency.
Themostwidely used prediction algorithms includemiRanda (miRBase
(Grifﬁths-Jones et al., 2006) and microrna.org (Enright et al., 2003)),
DIANA microT (Kiriakidou et al., 2004), PicTar (Krek et al., 2005) and
TargetScan/TargetScanS (Lewis et al., 2003, 2005). There are also meta-
databases of miRNA prediction algorithms that enable application of
multiple predictions such as, TargetCombo (Sethupathy et al., 2006)
and miRGen (Megraw et al., 2007). These interfaces provide access to
unions and intersections of these 4 most widely used target prediction
programs. As miRNA prediction methods typically predict large num-
bers of target genes, we incorporate a multi-hit approach that enriches
for target genes that contain three or more target sites for the altered
miRNA (Gardiner et al., 2011; Santarelli et al., 2011). Supporting this
method, Hon et al. (2007) proposed that target genes with more puta-
tive miRNA binding sites are expected to have more potential for
post-transcriptional regulation and greater intensity than those with
only one or two sites. This approach to ﬁltering target genes based on
the number of putative interactions, provides important strategy for in-
tegrating the inﬂuence of changes in multiple miRNA that can collec-
tively implicate many thousands of target genes. This is particularly
important when it comes to making sense of the combined effect of
multiple miRNA in pathway analysis.
To gain some appreciation of the biological implications of altered
miRNA expression in schizophrenia, many groups have examined pre-
dicted miRNA targets and their associated pathways using resources
such as the Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) (Dennis et al., 2003) and Ingenuity Pathway Analysis
(IPA) (http://www.ingenuity.com/products/pathways_analysis.html).
Postmortem studies of miRNA in schizophrenia have consistently
reported the over-represented of the neurally signiﬁcant KEGG path-
ways axon guidance, long term potentiation, focal adhesion and MAPK
signaling (Beveridge et al., 2008, 2010; Gardiner et al., 2011; Perkins
et al., 2007; Santarelli et al., 2011). Other groups that have utilized IPA
for assessing affected pathways have also consistently highlighted ner-
vous system development, function and disease as signiﬁcant pathways
represented by the miRNA target genes (Kim et al., 2010; Lai et al.,
2011). These pathway analyses have highlighted nervous system devel-
opment and processes involved in synaptic transmission asmajor effect
points of altered miRNA expression. These observations are consistent
with the disconnection hypothesis, which suggests that schizophrenia
is a phenomenon of abnormal synaptic plasticity because of inefﬁcient
or inappropriate wiring of neural networks (Friston, 1998).
Biological approaches to target validation
One of the advantages in understanding miRNA function is that
they interact with their mRNA targets through a somewhat predict-
able Watson–Crick, sequence-dependent manner. Despite the powerof these bioinformatic approaches, they are prone to both false posi-
tives and false negatives. To gain further biological insight into the
target genes of altered miRNA, in vitro assays have been established
to measure endogenous target gene activity in response to miRNA
transfection. This approach however does not distinguish between
the post-transcriptional inﬂuences of the transfected miRNA from
other secondary inﬂuences such as a change in transcription factors.
To achieve a more direct assessment of the relationship between a
miRNA and speciﬁc binding sites it is also important to investigate
the gene-miRNA interaction by reporter gene assay. In these assays
the target genes 3′UTR or speciﬁc miRNA recognition elements
(MRE) from are cloned into the 3′UTR of a ﬂuorescent or luminescent
reporter gene such as green ﬂuorescent protein or luciferase. As a
control measure, mutations may also be introduced into the seed-
pairing region of the binding site. The reporter gene activity, typically
luciferase, is then measured in response to transfection of synthetic
miRNA agonist (miRNA mimic) or antimiR antisense-antagonist
(antagomiR). Evidence of a canonical miRNA-mRNA interaction is
supported by the observation of an inverse relationship between
the miRNA concentration and reporter activity. This is demonstrated
by a decrease in reporter gene expression in response to miRNA
transfection or an increase in expression in response to antimiR trans-
fection that can suppress endogenous miRNA activity.
This approach was utilized by Mellios (2008) to substantiate the
miRNA-target gene relationship between BDNF and schizophrenia-
associated miRNA, miR-30a and miR-195 (Table 2). Relative lucifer-
ase activity was reduced upon transfection with synthetic versions
of the precursor transcripts. This method allows the precursor tran-
scripts to undergo processing by the endogenous miRNA pathway be-
fore eliciting their actions. Likewise, Begemann et al. (2010) used this
method to show that a cognition-relevant SNP (rs3822674) inﬂu-
enced the binding of miR-498 within the CPLX2 3′UTR and expression
of the gene. We also used this approach to investigate a number of
genes associated with synaptic function that were predicted targets
of functionally conserved miR-107 and the miR-15 family, dysregu-
lated in both the STG (BA22) and DLPFC (BA9) (Beveridge et al.,
2010) as well as DLPFC (BA46) in the case of miR-107 (Beveridge
et al., 2010; Santarelli et al., 2011). Since these miRNA share a highly
similar seed region, there was substantial overlap in predicted target
genes (including numerous schizophrenia candidate genes). A num-
ber of these targets were tested against the miR-15 family members
and miR-107 in response to transfection with synthetic versions of
the mature miRNA as well as antimiRs. The most consistently respon-
sive target MREs were derived from the 3′UTR of the schizophrenia
candidate genes GRIN3A and RELN, and miR-107 appeared to have
the greatest overall effect. A number of miRNA-target gene pairs dis-
played signiﬁcant bi-directional modulation, responding as expected
to both miRNA and anti-miR transfection (Table 2). Using the same
approach we also reported that schizophrenia-associated miR-181b
was able to repress VSNL1 and GRIA2 expression (Beveridge et al.,
2008).
Summary and future prospects
Schizophrenia has a complex neurobehavioural phenotype that is
thought to develop through disturbances in neural circuitry and syn-
aptic function. The complex mechanism and architecture of synapses
in the human brain requires coordination of an equally elaborate in-
tracellular network of molecular signal transduction systems. The re-
dundancy of these networks means that many combinations of gene
variants can give rise to system dysfunction that manifest as related
neurobehavioural syndromes. Posttranscriptional gene regulation
and small non-coding RNA are likely to be important factors shaping
the topography of this matrix. They are expressed in large numbers in
the brain and are emerging as key regulators ofmanyneurodevelopmen-
tal and neurological processes. Their dysregulation during development
Table 2
Supported schizophrenia-relevant miRNA/target relationships by reporter gene assay.
Schizophrenia-relevant target gene Reference
miRNA suppression of gene targets
miR-30a BDNF Mellios (2008)
miR-195 BDNF Mellios (2008)
miR-195 RGS4, GRIN3A, RELN Beveridge et al. (2010)
miR-107 DRD1 Beveridge et al. (2010)
miR-15a RGS4, GRM7, GRIN3A, VSNL1 Beveridge et al. (2010)
miR-15b RGS4, GRM7, HTR2A, RELN Beveridge et al. (2010)
miR-16 RGS4, GRIN3A, RELN, VSNL1, DLG4 Beveridge et al. (2010)
miR-498 CPLX2 Begemann et al. (2010)
Bi-directional modulation (both miRNA and anti-miR)
miR-181b GRIA2, VSNL1 Beveridge et al. (2008)
miR-107 RGS4, GRIN3A, RELN Beveridge et al. (2010)
miR-15a GRIN3A, RELN Beveridge et al. (2010)
miR-15b GRM7 Beveridge et al. (2010)
miR-219 CaMKIIγ Kocerha et al. (2009)
Gene abbreviations: BDNF: brain-derived neurotrophic factor, RGS4: regulator of
G-protein signaling 4, GRIN3A: glutamate [NMDA] receptor subunit 3A, RELN: reelin,
DRD1: dopamine receptor D1, GRM7: glutamate receptor metabotropic 7, VSNL1:
visinin-like 1, DLG4: disks large homolog 4 (also known as PSD-95 post synaptic den-
sity 95), GRIA2: glutamate receptor ionotropic AMPA 2.
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structure that are difﬁcult to understand but highly signiﬁcant to the un-
derlying pathophysiology and neuropathology of schizophrenia. This re-
view has cataloged mounting evidence that mature miRNA levels are
altered in both the cerebral cortex and peripheral blood mononuclear
cells. We have also examined evidence that suggests underlying
miRNA biogenesis machinery and the miRNA genes themselves are sub-
ject to genetic mutation and epigenetic inﬂuence. These are exempliﬁed
by CNVs and SNPs in the DGCR8/22q11 region andmiR-137 respectively,
which are both strongly associated with schizophrenia. Future work
should hopefully lead to more consensuses in the neuropathology, per-
haps by consideration of both the speciﬁc genetic and broader posttran-
scriptional underlying mechanisms regulating miRNA expression. With
so little known about the function of individualmiRNA and the biological
implications of their dysregulation in the developing andmature brain, it
will be important to characterize these molecules better at the molecu-
lar, cellular, developmental and ultimately neurobehavioural levels. At
one end of this spectrum, there are a number of high throughput meth-
odologies that are unlocking the mysteries of miRNA targeting, while at
the other end, several model systems including transgenic zebraﬁsh
and rodent models that are taking up the challenge of investigating the
role of miRNA in development and behavior. These model systems not
only provide the basis for understanding the phenotype of miRNA dys-
function, they provide a platform for the investigating therapeutics.
miRNA and the underlying miRNA biogenesis machinery are potentially
both novel drug targets and newdrug entities in theﬁght to control neu-
ropsychiatric conditions.With the identiﬁcation of miRNA biomarkers in
PBMCs and other peripheral sources, the clinical development of miRNA
oriented pharmaceutical interventionsmay be accompanied bymiRNA-
based clinical diagnostics. New biomarkers for schizophrenia and asso-
ciated phenotypes could ultimately provide the basis for earlier detec-
tion, disease stratiﬁcation and the prediction of response to drugs and
side effects. Gathering a better appreciation of the role of miRNA in
the brain and in neuropsychiatric disorders such as schizophrenia is
an enormous challenge, but the potential signiﬁcance of these discoveries
are likely to be highly signiﬁcant.
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